4.7 Review

Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 144, Issue -, Pages 843-858

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2017.11.103

Keywords

GSK-3 inhibitors; Alzheimer's; Diabetes; Cancer; Neurodegeneration

Funding

  1. CSIR-Indian Institute of Chemical Technology
  2. National Institute of Pharmaceutical Education and Research, Hyderabad

Ask authors/readers for more resources

Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine kinase which is ubiquitously expressed and is regarded as a regulator for various cellular events and signalling pathways. It exists in two isoforms, GSK-3 alpha and GSK-3 beta and can phosphorylate a wide range of substrates. Aberrancy in the GSK-3 activity can lead to various diseases like Alzheimer's, diabetes, cancer, neurodegeneration etc., rendering it an attractive target to develop potent and specific inhibitors. The present review focuses on the recent developments in the area of GSK-3 inhibitors and also enlightens its therapeutic applicability in various disease conditions. (C) 2017 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available